|
EP1761561B1
(en)
|
2004-01-20 |
2015-08-26 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
|
DK1713503T3
(da)
*
|
2004-02-10 |
2013-11-04 |
Univ Colorado Regents |
Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
|
|
AU2005306502B2
(en)
|
2004-11-16 |
2012-11-15 |
Humanigen, Inc. |
Immunoglobulin variable region cassette exchange
|
|
ES2548700T3
(es)
|
2005-05-26 |
2015-10-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
|
|
US8211648B2
(en)
|
2005-07-22 |
2012-07-03 |
Kalobios Pharmaceuticals, Inc. |
Secretion of antibodies without signal peptides from bacteria
|
|
GB0525662D0
(en)
*
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
|
WO2007085814A1
(en)
*
|
2006-01-24 |
2007-08-02 |
Domantis Limited |
Fusion proteins that contain natural junctions
|
|
EP1918302A3
(en)
*
|
2006-05-18 |
2009-11-18 |
AvantGen, Inc. |
Methods for the identification and the isolation of epitope specific antibodies
|
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
|
US20080171038A1
(en)
*
|
2006-11-08 |
2008-07-17 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
|
|
US8398972B2
(en)
*
|
2006-11-21 |
2013-03-19 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating dementia using a GM-CSF antagonist
|
|
CN105435223A
(zh)
|
2006-11-21 |
2016-03-30 |
卡罗拜奥斯制药公司 |
使用gm-csf拮抗剂治疗慢性炎症疾病的方法
|
|
JP2010520748A
(ja)
*
|
2007-02-20 |
2010-06-17 |
アナプティスバイオ インコーポレイティッド |
体細胞超変異系
|
|
PT3199180T
(pt)
*
|
2007-03-08 |
2022-04-01 |
Univ Monash |
Anticorpos epha3 para o tratamento de tumores sólidos
|
|
AU2008251943B2
(en)
|
2007-03-14 |
2013-09-05 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
WO2008154439A1
(en)
*
|
2007-06-08 |
2008-12-18 |
Irm Llc |
Methods and compositions for inducing apoptosis in cancer cells
|
|
KR20100021657A
(ko)
*
|
2007-07-17 |
2010-02-25 |
아이알엠 엘엘씨 |
프로테아제 활성화된 수용체-１ (ｐａｒ１)의 길항제 항체
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
EA201000903A1
(ru)
|
2007-11-30 |
2011-02-28 |
Калобиос Фармасьютикалс, Инк. |
Антитела к pcrv-антигену pseudomonas aeruginosa
|
|
KR101259239B1
(ko)
*
|
2008-01-10 |
2013-04-29 |
시오노기세야쿠 가부시키가이샤 |
ＰｃｒＶ에 대한 항체
|
|
EA201001691A1
(ru)
|
2008-04-28 |
2011-10-31 |
Калобайос Фармасьютикалз, Инк. |
Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
|
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
|
WO2010043977A2
(en)
|
2008-10-13 |
2010-04-22 |
Institute For Research In Biomedicine |
Dengue virus neutralizing antibodies and uses thereof
|
|
CA2751433A1
(en)
|
2009-02-04 |
2010-08-12 |
Kalobios Pharmaceuticals, Inc. |
Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
|
|
WO2010093814A1
(en)
|
2009-02-11 |
2010-08-19 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating dementia using a gm-csf antagonist
|
|
NZ594950A
(en)
|
2009-03-06 |
2013-06-28 |
Kalobios Pharmaceuticals Inc |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
|
PT2407537E
(pt)
*
|
2009-03-11 |
2015-02-17 |
Shionogi & Co |
Anticorpo pcrv humanizado com atividade anti-pseudomonal
|
|
NO2424895T3
(enExample)
|
2009-04-27 |
2018-02-03 |
|
|
|
BRPI1016055A2
(pt)
|
2009-04-27 |
2016-05-10 |
Novartis Ag |
composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
|
|
CN102459591B
(zh)
*
|
2009-05-20 |
2015-05-13 |
诺维莫尼公司 |
合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
|
|
AU2010266127B2
(en)
|
2009-07-02 |
2015-11-05 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
PT2488554T
(pt)
*
|
2009-10-14 |
2019-09-13 |
Humanigen Inc |
Anticorpos para epha3
|
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
WO2011092593A2
(en)
|
2010-01-20 |
2011-08-04 |
Institute For Research In Biomedicine |
Hiv-1 neutralizing antibodies and uses thereof
|
|
EP4219560A3
(en)
|
2010-02-18 |
2023-08-23 |
The Regents of The University of California |
Integrin alpha v beta 8 neutralizing antibody
|
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
|
EP2673302A1
(en)
|
2011-02-11 |
2013-12-18 |
Irm Llc |
Pcsk9 antagonists
|
|
ES2926988T3
(es)
|
2011-03-15 |
2022-10-31 |
X Body Inc |
Métodos de cribado de anticuerpos
|
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
PL2726099T3
(pl)
|
2011-07-01 |
2018-12-31 |
Novartis Ag |
Sposób leczenia zaburzeń metabolicznych
|
|
US9790280B2
(en)
|
2011-10-26 |
2017-10-17 |
Elanco Tiergesundheit Ag |
Monoclonal canine CD20 antibodies and methods of use
|
|
EP2788382A2
(en)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
CA2859493A1
(en)
|
2011-12-21 |
2013-06-27 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
HRP20210517T1
(hr)
|
2012-12-05 |
2021-05-14 |
Novartis Ag |
Pripravci i postupci za protutijela usmjerena na epo
|
|
KR20150095684A
(ko)
|
2012-12-18 |
2015-08-21 |
노파르티스 아게 |
히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
|
|
BR112015017560A2
(pt)
*
|
2013-01-24 |
2018-05-15 |
Scripps Korea Antibody Institute |
biblioteca de fv à base de combinação de proteína e modo de preparação da mesma
|
|
AP2015008584A0
(en)
|
2013-02-08 |
2015-07-31 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
KR20160042871A
(ko)
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
MX374317B
(es)
|
2013-06-28 |
2025-03-06 |
X Body Inc |
Selecciones fenotípicas, descubrimiento del antígeno objetivo y uso de los mismos para la identificación de epítopes objetivo específicos de células objetivo.
|
|
TW201536318A
(zh)
|
2013-08-14 |
2015-10-01 |
Novartis Ag |
治療偶發性包涵體肌炎之方法
|
|
SMT201900714T1
(it)
|
2013-12-09 |
2020-01-14 |
Allakos Inc |
Anticorpi anti-siglec-8 e loro metodi d'impiego
|
|
US10287637B2
(en)
|
2014-01-25 |
2019-05-14 |
uBiome, Inc. |
Method and system for microbiome analysis
|
|
EP4014995A1
(en)
|
2014-02-28 |
2022-06-22 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
WO2015188839A2
(en)
|
2014-06-13 |
2015-12-17 |
Immudex Aps |
General detection and isolation of specific cells by binding of labeled molecules
|
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
SG10201805646WA
(en)
|
2014-08-07 |
2018-08-30 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
EP3283512A4
(en)
|
2015-04-17 |
2018-10-03 |
Distributed Bio Inc |
Method for mass humanization of non-human antibodies
|
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
US10774145B2
(en)
|
2015-06-17 |
2020-09-15 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
US11001900B2
(en)
|
2015-06-30 |
2021-05-11 |
Psomagen, Inc. |
Method and system for characterization for female reproductive system-related conditions associated with microorganisms
|
|
EP3317428A4
(en)
|
2015-06-30 |
2018-12-19 |
Ubiome Inc. |
Method and system for diagnostic testing
|
|
KR102728071B1
(ko)
|
2015-08-03 |
2024-11-11 |
노파르티스 아게 |
Fgf21-연관 장애를 치료하는 방법
|
|
RS61763B1
(sr)
|
2015-09-09 |
2021-05-31 |
Novartis Ag |
Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
|
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
|
JP6654779B2
(ja)
*
|
2015-10-13 |
2020-02-26 |
株式会社バイオピーク |
ターゲットを認識するタンパク質の発現スクリーニング法
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
BR112018010937A2
(pt)
|
2015-12-04 |
2018-12-04 |
Novartis Ag |
composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子１５に対する抗体およびそれらの使用
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
CN110381988A
(zh)
|
2016-06-15 |
2019-10-25 |
诺华股份有限公司 |
使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
|
|
US20190270821A1
(en)
|
2016-09-13 |
2019-09-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
|
CN110366558A
(zh)
|
2016-10-28 |
2019-10-22 |
班扬生物标记公司 |
针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
|
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
|
AU2017383232B2
(en)
|
2016-12-23 |
2024-09-12 |
Novartis Ag |
Factor XI antibodies and methods of use
|
|
JP6991246B2
(ja)
|
2017-02-08 |
2022-02-03 |
ノバルティス アーゲー |
Ｆｇｆ２１模倣抗体及びその使用
|
|
CA3054837A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
EA201992626A1
(ru)
|
2017-05-05 |
2020-04-24 |
Аллакос Инк. |
Способы и композиции для лечения аллергических заболеваний глаз
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
JP2020525421A
(ja)
|
2017-06-28 |
2020-08-27 |
ノバルティス アーゲー |
尿失禁を予防及び治療するための方法
|
|
EP3625254B1
(en)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Three-dimensional structure-based humanization method
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019102353A1
(en)
|
2017-11-22 |
2019-05-31 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
AR117343A1
(es)
|
2018-12-18 |
2021-07-28 |
Novartis Ag |
AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
CN116917325A
(zh)
|
2021-03-01 |
2023-10-20 |
西里欧发展公司 |
用于治疗癌症的被掩蔽的ctla4和pd1/pdl1抗体的组合
|